Putting its piv­otal fail­ure in the rearview mir­ror, As­traZeneca scores an EU nod for its lu­pus drug

Af­ter a bumpy road to ap­proval in the US, As­traZeneca is tout­ing a nod for Saph­ne­lo in the EU to treat mod­er­ate to se­vere sys­temic lu­pus ery­the­mato­sus (SLE), an au­toim­mune dis­ease in which the im­mune sys­tem at­tacks healthy tis­sue in the body.

The news doesn’t come as much of a sur­prise, as the EMA’s Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use (CHMP) of­fered up a pos­i­tive rec­om­men­da­tion for the drug back in De­cem­ber. In­vestors were most­ly mut­ed on Wednes­day morn­ing, with $AZN stock up less than 1%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER